COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments

finance.yahoo.com/news/covid-19-vaccine-maker-biontech-142518112.html

In This Article:
Key Takeaways
-
BioNTech is buying fellow German firm CureVac for approximately $1.25 billion as the COVID-19 vaccine maker moves to expand into cancer treatments.
-
For each CureVac share they own, investors will get about $5.46 worth of BioNTech American Depositary…

This story appeared on finance.yahoo.com, 2025-06-12 14:25:18.
The Entire Business World on a Single Page. Free to Use →